Delivery Order SPE2DB20D1100-SPE2DB24FD3L4

Award Date 8/19/24
Potential Completion Date 8/20/24
Potential Value $2.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,803.61 firm fixed-price contract is for the supply of RESTASIS 0.05% eye emulsion. The contract has an ultimate completion date of January 3, 2025 and is not designated as a set-aside requirement. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,569.36 firm fixed-price contract is for the supply of RESTASIS 0.05% eye emulsion. It is a non-set-aside award with a completion date of August 8, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The $34,149.58 firm-fixed-price contract has a completion date of May 24, 2024. No set-aside designation was used. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,160.96, is for the delivery of RESTASIS 0.05% eye emulsion, with a completion date of February 15, 2023. The contract is a firm fixed-price, delivery order type, and was not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a significant...
This federal contract award, valued at $8,018.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp. for the delivery of RESTASIS 0.05% eye emulsion in 60-count packages. The contract is a Firm Fixed Price Delivery Order with a completion date of November 27, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $7,733.01, is for a delivery order of RESTASIS 0.05% eye emulsion with an ultimate completion date of November 26, 2024. The contract is a firm fixed-price agreement with no set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Restasis 0.05% eye emulsion. The contract has a ceiling value of $2,481.01 and runs through December 14, 2023. It is a firm fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,948.36 firm-fixed-price delivery order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The $8,478.17 firm fixed-price contract has an ultimate completion date of July 20, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
The Defense Logistics Agency (DLA) awarded a $6,922.41 firm-fixed price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division for the supply of RESTASIS 0.05% eye emulsion. The contract has an ultimate completion date of August 23, 2024 and is not a set-aside. Amerisourcebergen is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts (IDCs) with federal agencies, including a $999,999,999 IDC with DLA Troop Support Medical through...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB24FD3L4
    Delivery Order

This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for RESTASIS 0.05% eye emulsion. The contract has a Firm Fixed Price of $2,160.96 and an ultimate completion date of August 20, 2024. The order is not a set-aside contract. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, to provide a wide range of medical commodities, including pharmaceuticals, to support military treatment programs and facilities worldwide. The company has also been awarded other federal contracts by agencies such as the Department of Justice Federal Bureau of Investigation to supply essential medical products and prescription drugs.

Generated 11/18/24, 9:48 AM